What is the appropriate management of bradycardia in a patient receiving a lacosamide infusion?

Management of Bradycardia During Lacosamide Infusion

Immediately stop the lacosamide infusion if symptomatic bradycardia develops, as lacosamide is a known cause of dose-dependent cardiac conduction abnormalities including bradycardia, AV block, and has been associated with cardiac arrest in rare cases 1.

Initial Assessment and Immediate Actions

When bradycardia occurs during lacosamide infusion:

1. Stop the infusion immediately - Lacosamide causes dose-dependent PR interval prolongation and can precipitate profound bradycardia, particularly during IV administration 1

2. Assess for symptoms of hemodynamic compromise:

   • Acute altered mental status
   • Ischemic chest discomfort
   • Acute heart failure
   • Hypotension (systolic BP <80-90 mmHg)
   • Signs of shock
   • Syncope 2, 3

3. Ensure adequate oxygenation - Check oxygen saturation and provide supplemental oxygen if hypoxemic 3

4. Obtain 12-lead ECG to identify the rhythm and assess for AV block or PR prolongation 2, 3

5. Establish IV access and continuous cardiac monitoring 3

Pharmacologic Management

For Symptomatic Bradycardia (Heart Rate <50 bpm with hemodynamic compromise):

First-line: Atropine 2, 3, 2

• Dose: 0.5-1 mg IV every 3-5 minutes to maximum total dose of 3 mg 2, 3, 4
• Most effective for sinus bradycardia and AV nodal block
• Caution: Doses <0.5 mg may paradoxically slow heart rate 2, 5
• Avoid in Mobitz type II or third-degree AV block with wide QRS (infranodal block), as atropine is unlikely to be effective 3, 5

If Atropine Fails or is Contraindicated:

Second-line options (Class IIa-IIb) 2, 4:

• Dopamine: 5-20 mcg/kg/min IV, starting at 5 mcg/kg/min, increasing by 5 mcg/kg/min every 2 minutes 2, 4

  • Doses >20 mcg/kg/min may cause vasoconstriction or arrhythmias

• Epinephrine: 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min IV titrated to effect 2, 4

• Isoproterenol: 20-60 mcg IV bolus or 1-20 mcg/min infusion 2, 4

  • Avoid if coronary ischemia suspected - increases myocardial oxygen demand while decreasing coronary perfusion 2

Transcutaneous Pacing

Consider immediate transcutaneous pacing (TCP) if:

• Bradycardia is unresponsive to atropine 3, 6
• Patient has Mobitz type II or third-degree AV block 5
• Severe hemodynamic instability present 5, 3

TCP is a temporizing measure while preparing for transvenous pacing if needed 3, 6. Administer with medical supervision and provide sedation in conscious patients as TCP is painful 3.

Special Considerations for Lacosamide-Induced Bradycardia

Sodium Bicarbonate as Rescue Therapy

Consider sodium bicarbonate for severe conduction abnormalities, particularly if wide QRS complex is present 7. This has been reported as effective "bail-out therapy" for lacosamide-induced critical conduction delays, similar to its use in sodium channel blocker toxicity.

Risk Factors Requiring Enhanced Vigilance

Lacosamide should be used with extreme caution or avoided in patients with 1:

• Pre-existing cardiac conduction problems (first-degree AV block, second-degree or higher AV block, sick sinus syndrome without pacemaker)
• Severe cardiac disease (myocardial ischemia, heart failure, structural heart disease)
• Cardiac sodium channelopathies (e.g., Brugada Syndrome)
• Concomitant medications affecting cardiac conduction (other sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers)
• Baseline bradycardia 8

Critical Pitfalls

1. Lacosamide can cause profound bradycardia even during the infusion itself - One case reported profound bradycardia during a 15-minute infusion of 150 mg 1

2. Young, healthy patients are not immune - Second-degree AV block has occurred in healthy young athletes with baseline bradycardia within hours of IV lacosamide 8

3. Additive effects with other AEDs - Concomitant use with carbamazepine, eslicarbazepine, or other sodium channel blockers dramatically increases risk of high-degree AV block 9, 10

4. Bradycardia may be asystole precursor - Postmarketing reports include progression to asystole, cardiac arrest, and death 1

Post-Event Management

• Do not restart lacosamide if it caused symptomatic bradycardia or high-degree AV block
• Obtain cardiology consultation for patients who developed second-degree or higher AV block
• Consider alternative antiseizure medications without cardiac conduction effects
• Monitor with continuous telemetry until rhythm stabilizes and lacosamide is cleared (elimination half-life ~13 hours)

The reversibility of lacosamide-induced conduction abnormalities is well-documented, with complete resolution typically occurring after drug discontinuation 9, 8, 10.